34
1
7
↑34
↓1
—7
Evidence suggests Melatonin mayincreaseEfficacy.
37 studies (42 claims)
Strong consensus
Typical effective dose 10.5 (3.75–22.5) mgacross 6 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| oral melatonin 3 mg | Increases - hypnotic efficacy was better than oral L-theanine 200 mg | hypnotic efficacy | Human | cancer patients having insomnia | 200 mg, taken once daily two hours before bedtime | Comparison Between Efficacy of Oral Melatonin and Oral L-theanine in Improving Sleep in Cancer Patients Suffering From Insomnia: A Randomised Double-blinded Placebo-controlled Study.cited 2× |
| oral melatonin | Increases - significant differences in favour of melatonin treatment were found | hypnotic efficacy | Human | cancer patients with insomnia | 200 mg, taken once daily two hours before bedtime | Comparison Between Efficacy of Oral Melatonin and Oral L-theanine in Improving Sleep in Cancer Patients Suffering From Insomnia: A Randomised Double-blinded Placebo-controlled Study.cited 2× |
| preoperative oral melatonin medication | Increases - was significantly different | subjective analgesic efficacy | Human | patients undergoing elective prostatectomy | 6 mg melatonin the night before and 1 hour before surgery. | Effects of preoperative oral melatonin medication on postoperative analgesia, sleep quality, and sedation in patients undergoing elective prostatectomy: a randomized clinical trial.cited 61× |
| melatonin | Increases - enhancing chemotherapeutic efficacy | chemotherapeutic efficacy | Human | osteosarcoma patients | Not specified | Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations.cited 7× |
| melatonin | Increases - excellence rates of patients were 82.75% and 30.00%, respectively | clinical efficacy | Human | AOPP patients with subsequent delirium | Not specified | Observation and analysis of clinical efficacy of melatonin on AOPP-induced delirium patients.cited 6× |
| melatonin | No effect - no significant difference | clinical efficacy outcomes | Human | patients with relapsing-remitting multiple sclerosis (RRMS) | 25 mg/d orally. | Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.cited 65× |
| melatonin | Decreases - symptomatic therapy | Clinical Global Impression (CGI) efficacy index | Human | patients with rapid eye movement sleep behavior disorder (RBD) | Not specified | Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.cited 161× |
| melatonin | No effect - no difference was revealed | efficacy | Human | adults with migraine | Not specified in the abstract. | Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis.cited 41× |
| melatonin | Increases - was more effective | efficacy | Human | adults with migraine | Not specified in the abstract. | Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis.cited 41× |
| melatonin | No effect - evidence for its efficacy is inconclusive | efficacy | Human | people with Alzheimer's disease | Not specified | Pharmacological interventions to improve sleep in people with Alzheimer's disease: a meta-analysis of randomized controlled trials.cited 3× |
| melatonin | No effect - few studies document | efficacy and safety | Human | these populations | Not specified | Melatonin Treatment in Children with Developmental Disabilities.cited 28× |
| melatonin | No effect - show how it could be evaluated, but with no conclusive evidence of efficacy and safety | efficacy and safety | HumanMolecular | clinical trials | Not specified | Assessing the antiviral potential of melatonin: A comprehensive systematic review.cited 6× |
| melatonin | Increases - increasing their efficacy | efficacy of anti-cancer drugs | Human | — | Not specified | Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.cited 310× |
| melatonin | Increases - increases | efficacy of chemotherapeutic agents | Molecular | treatment of breast cancer | — | Melatonin: A Potential Antineoplastic Agent in Breast Cancer. |
| melatonin | Increases - increases | efficacy of chemotherapeutic agents | Molecular | treatment of breast cancer | — | Melatonin: A Potential Antineoplastic Agent in Breast Cancer. |
| Melatonin | Increases - increase | efficacy of oncostatic drugs | Molecular | animal studies | High doses (specific amounts not stated) for pro-apoptotic effects; low doses for anti-apoptotic effects. | Melatonin influences pancreatic cancerogenesis.cited 18× |
| melatonin | Increases - enhancing the efficacy | efficacy of other drugs | HumanMolecular | — | Not specified | Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.cited 12× |
| melatonin | Increases - may increase | the efficacy of COVID-19 vaccination | Human | — | Not specified | Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders.cited 22× |
| melatonin | Increases - demonstrates positive synergistic effects with other anti-sepsis agents | therapeutic efficacy | Human | sepsis | Not specified | Melatonin Exerts Positive Effects on Sepsis Through Various Beneficial Mechanisms. |
| Melatonin | Increases - reinforcement of therapeutic effects | therapeutic efficacy | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| Melatonin | Increases - reinforcement of therapeutic effects | therapeutic efficacy | Molecular | — | Not specified | Melatonin and its ubiquitous anticancer effects. |
| melatonin | Increases - improving its therapeutic efficacy | therapeutic efficacy of chemotherapy | Human | — | Not specified | The Role of Melatonin in Colorectal Cancer.cited 15× |
| adjuvant treatment with melatonin | Increases - was found to be superior to the placebo | clinical efficacy | Human | patients with chronic migraine | 3 mg melatonin daily. | Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial.cited 41× |
| adjuvant treatment with melatonin | No effect - had the same clinical efficacy as sodium valproate | clinical efficacy | Human | patients with chronic migraine | 3 mg melatonin daily. | Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial.cited 41× |
| low dose buspirone 15 mg combined with melatonin-SR 3 mg | Increases - yielded optimal antidepressant efficacy | antidepressant efficacy | HumanAnimalMolecular | pre-clinical platform | Melatonin-SR 3 mg combined with buspirone 15 mg | An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.cited 43× |
| prolonged-release melatonin formulation (PRM; Circadin 2 mg) | No effect - no signs of tolerance | efficacy | Human | insomnia patients | 2 mg once daily, 2 hours before bedtime. | Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.cited 72× |
| melatonin-coated lactoferrin-chitosan nanoparticles (ETP-CS-LF-MLT-NPs) | Increases - Enhanced cellular uptake due to lactoferrin targeting improved | therapeutic efficacy | HumanAnimalMolecular | HCT116 cells | Not specified in the abstract. | Fabrication of lactoferrin-chitosan-etoposide nanoparticles with melatonin via carbodiimide coupling: In-vitro & in-vivo evaluation for colon cancer.cited 2× |
| concomitant administration of melatonin with other conventional chemotherapy agents | Increases - had beneficial effects | efficacy of those agents | Human | patients with breast cancer | Not specified | Melatonin, an inhibitory agent in breast cancer.cited 68× |
| Melatonin and nutraceuticals | Increases - with good results in terms of perceived efficacy and tolerability | perceived efficacy and tolerability | Human | subjects | Not specified | Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study.cited 23× |
| melatonin to augment HT | No effect - has been studied | safety and efficacy | Human | neonatal piglet model of perinatal asphyxia | 15-30 mg/L (therapeutic levels). | Melatonin for Neonatal Encephalopathy: From Bench to Bedside.cited 12× |
| melatonin replacement therapy | Increases - only in the early phases of the disease and in cases where the melatonin receptors are intact and functioning | therapeutic efficacy | Human | AD patients in early phases with intact melatonin receptors | — | The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease.cited 1× |
| Melatonin signaling via melatonin receptor type 1 (MT1) | Increases - enhances | therapeutic efficacy of androgen deprivation therapy | AnimalMolecular | castration-resistant prostate cancer models | — | Disruption of Melatonin Signaling Leads to Lipids Accumulation in the Liver of Melatonin Proficient Mice. |
| melatonin therapy | Increases - might potentially improve | efficacy of mechanical reperfusion with primary percutaneous coronary intervention (pPCI) | Human | patients with STEMI | Intravenous and intracoronary bolus (specific amounts not detailed). | Usefulness of Early Treatment With Melatonin to Reduce Infarct Size in Patients With ST-Segment Elevation Myocardial Infarction Receiving Percutaneous Coronary Intervention (From the Melatonin Adjunct in the Acute Myocardial Infarction Treated With Angioplasty Trial).cited 57× |
| melatonin therapy | Increases - marginally improved | sleep efficacy (SE) | Human | patients with dementia | Not specified | Melatonin for sleep disorders and cognition in dementia: a meta-analysis of randomized controlled trials.cited 77× |
| adjunctive use of melatonin in schizophrenia | Increases - may augment the efficacy of antipsychotics | efficacy of antipsychotics | Human | schizophrenic patients | Not specified | Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.cited 59× |
| melatonin as a complementary agent with 5-FU-based chemotherapy | Increases - enhance the efficacy | efficacy of the combined therapy | Human | — | — | Melatonin and 5-fluorouracil combination chemotherapy: opportunities and efficacy in cancer therapy.cited 36× |
| melatonin as an add-on treatment | No effect - to assess the efficacy and safety | efficacy and safety | Human | Participants aged 3 months to 2 years with a primary diagnosis of infantile epileptic spasms syndrome (IESS) | Not available | Safety and efficacy of melatonin supplementation as an add-on treatment for infantile epileptic spasms syndrome: A randomized, placebo-controlled, double-blind trial.cited 5× |